Back to Journals » Journal of Experimental Pharmacology » Volume 13

Montelukast: The New Therapeutic Option for the Treatment of Epilepsy

Authors Tesfaye BA, Hailu HG, Zewdie KA, Ayza MA, Berhe DF

Received 22 August 2020

Accepted for publication 29 December 2020

Published 20 January 2021 Volume 2021:13 Pages 23—31

DOI https://doi.org/10.2147/JEP.S277720

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Jun Chen


Bekalu Amare Tesfaye, Haftom Gebregergs Hailu, Kaleab Alemayehu Zewdie, Muluken Altaye Ayza, Derbew Fikadu Berhe

Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, Ethiopia

Correspondence: Haftom Gebregergs Hailu Tel +251912085606
Fax +251344416681
Email haftomphar@gmail.com

Abstract: Currently, there is no definitive cure for epilepsy. The available medications relieve symptoms and reduce seizure attacks. The major challenge with the available antiepileptic medication is safety and affordability. The repurposing of montelukast for epilepsy can be an alternative medication with a better safety profile. Montelukast is a leukotriene receptor antagonist that binds to the cysteinyl leukotrienes (CysLT) receptors used in the treatment of bronchial asthma and seasonal allergies. Emerging evidence suggests that montelukast’s anti-inflammatory effect can help to maintain BBB integrity. The drug has also neuroprotective and anti-oxidative activities to reduce seizure incidence and epilepsy. The present review summarizes the neuropharmacological actions of montelukast in epilepsy with an emphasis on the recent findings associated with CysLT and cell-specific effects.

Keywords: repurposing, seizure, inflammation, cysteinyl leukotriene receptors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]